Need more information in your inbox? Digging for more data? A premium subscription provides both full text email alerts and access to archived news.
Support Biomarker CommonsNeed more information in your inbox? Digging for more data? A premium subscription provides both full text email alerts and access to archived news. Biomarker Commons JobsLatest Biomarker NewsSearch Biomarker NewsBiomarker News Email AlertsReach your targeted audience: advertise with us |
pharmacogenomicsUniversity of Maryland Medical Center Launches Genetic-Testing Program For Cardiac Stent PatientsPatients with coronary artery disease who undergo treatment at the University of Maryland Medical Center now can receive long-term therapy based on information found in their genes. As part of a new personalized medicine initiative, the medical center is offering genetic testing to help doctors determine which medication a patient should take after a stenting procedure in order to prevent blood clots that could lead to serious – and potentially fatal – heart attacks and strokes.
Tags:
QIAGEN Acquires Ingenuity Systems, Adding Leading Solution for Analysis and Interpretation of Complex Biological DataQIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of Ingenuity Systems, Inc., the leading provider of software solutions to efficiently and accurately analyze and interpret the biological meaning of genomic data. Ingenuity, a privately-held U.S. company based in California’s Silicon Valley, has created the market leading expertly curated knowledge system of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
|